Bio-Thera Solutions (SHSE:688177) ROE %: -202.39% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688177 Bio-Thera Solutions Ltd SHSE:688177
53 GF Score
Price ¥16.58
GF Value ¥33.46
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Bio-Thera Solutions ROE %?

Bio-Thera Solutions SHSE:688177 -3.38% 53 ROE % is -202.39% as of Mar. 2026. GuruFocus rates SHSE:688177 with a GF Score™ of 53/100 and a GF Value™ of ¥33.46 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,251 Biotechnology companies, Bio-Thera Solutions ranks worse than 71.7% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Bio-Thera Solutions's annualized net income for the quarter that ended in Mar. 2026 was ¥-607.3 Mil. Bio-Thera Solutions's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was ¥300.1 Mil. Therefore, Bio-Thera Solutions's annualized ROE % for the quarter that ended in Mar. 2026 was -202.39%.

The historical rank and industry rank for Bio-Thera Solutions's ROE % or its related term are showing as below:

SHSE:688177' s ROE % Range Over the Past 10 Years
Min: -142.82   Med: -46.04   Max: 4
Current: -85.54

During the past 10 years, Bio-Thera Solutions's highest ROE % was 4.00%. The lowest was -142.82%. And the median was -46.04%.

SHSE:688177's ROE % is ranked worse than
71.7% of 1251 companies
in the Biotechnology industry
Industry Median: -38.61 vs SHSE:688177: -85.54

Bio-Thera Solutions  (SHSE:688177) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-607.34/300.077
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-607.34 / 1006.348)*(1006.348 / 2336.2135)*(2336.2135 / 300.077)
=Net Margin %*Asset Turnover*Equity Multiplier
=-60.35 %*0.4308*7.7854
=ROA %*Equity Multiplier
=-26 %*7.7854
=-202.39 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-607.34/300.077
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-607.34 / -607.292) * (-607.292 / -583.012) * (-583.012 / 1006.348) * (1006.348 / 2336.2135) * (2336.2135 / 300.077)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0001 * 1.0416 * -57.93 % * 0.4308 * 7.7854
=-202.39 %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Bio-Thera Solutions ROE % Related Terms


Bio-Thera Solutions ROE % Historical Data

* Premium members only.

The historical data trend for Bio-Thera Solutions's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Thera Solutions ROE % Chart

Bio-Thera Solutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 -26.00 -27.98 -53.13 -61.24

Bio-Thera Solutions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -56.44 -21.11 -74.15 -100.52 -202.39

SHSE:688177 vs VRTX, REGN, ALNY: ROE % Comparison

For the Biotechnology subindustry, Bio-Thera Solutions's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Thera Solutions ROE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Thera Solutions's ROE % distribution charts can be found below:

* The bar in red indicates where Bio-Thera Solutions's ROE % falls into.


SHSE:688177
53GF Score
Bio-Thera Solutions Ltd SHSE:688177
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Thera Solutions ROE % Calculation

Bio-Thera Solutions's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=-331.941/( (708.089+376.031)/ 2 )
=-331.941/542.06
=-61.24 %

Bio-Thera Solutions's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=-607.34/( (376.031+224.123)/ 2 )
=-607.34/300.077
=-202.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of -202.39% mean?
Bio-Thera Solutions (SHSE:688177) has a ROE % of -202.39% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Bio-Thera Solutions and its competitors. According to the industry distribution chart, Bio-Thera Solutions ranks #897 out of 1251 companies in the Biotechnology industry, placing it in the top 71.7%.
Is Bio-Thera Solutions' ROE % too high?
Bio-Thera Solutions' current ROE % is -202.39%. Based on the distribution chart, Bio-Thera Solutions ranks #897 out of 1251 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bio-Thera Solutions has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bio-Thera Solutions' ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bio-Thera Solutions ranks #897 out of 1251 companies for ROE %. This places Bio-Thera Solutions in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Bio-Thera Solutions and its competitors. Bio-Thera Solutions's current ROE % is -202.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Thera Solutions stock overvalued right now?
Based on GuruFocus' analysis, Bio-Thera Solutions (SHSE:688177) is currently considered Possible Value Trap. The stock's GF Value™ is ¥33.46, compared to a current price of ¥16.58 — trading 50.4% below its estimated fair value. The current ROE % is -202.39%. Bio-Thera Solutions' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Bio-Thera Solutions (SHSE:688177), the current ROE % is -202.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Thera Solutions (SHSE:688177) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Thera Solutions stock appears to be undervalued. The current stock price of ¥16.58 is trading 50.4% below its estimated GF Value™ of ¥33.46. GuruFocus considers Bio-Thera Solutions to be Possible Value Trap.

Key valuation signals for SHSE:688177:

  • ROE %: -202.39%
  • GF Value™: ¥33.46 vs. price of ¥16.58 (50.4% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the SHSE:688177 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bio-Thera Solutions Business Description

Address 5th Floor, Building A6, 11 Kaiyuan Avenue, Guangzhou High-tech Industrial Development Zone, Science City, Guangdong Province, Guangzhou, CHN, 510530
Bio-Thera Solutions Ltd is engaged in research, development, and production of drugs and biosimilars. The company provides drug research and development; biotechnology consulting and communication services; services; medical research and experimental development; biological drug manufacturing; and pharmaceuticals retail.
53GF Score

Get the complete analysis for SHSE:688177

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥16.58
Price
¥33.46
GF Value